Judicate West Continues Southern California Growth with Addition of Employment Neutral Michael Strauss
LOS ANGELES, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Judicate West, one of California's leading providers of private dispute resolution services, has added Michael Strauss, Esq. to its roster of neutrals. Based out of the Los Angeles office, Strauss is available statewide as a mediator and arbitrator.
'Mike brings a wealth of employment law experience to our Employment Practice Group, having spent more than 18 years representing plaintiffs and defendants in almost every type of employment dispute. As a client, using our neutrals over the years, Mike earned a reputation as a fair and respectful negotiator and effective settlement driver. His patient, persistent, and practical style fits perfectly with our culture and fellow neutrals,' said Rosemarie Chiusano Aubert, Co-Founder and Executive Vice President of Business Development with Judicate West. 'We are excited to work with Mike and offer his services to our clients statewide. We expect they will be as impressed with him as we are.'
Strauss has more than 18 years of experience in labor and employment law, representing individuals and companies in wage-and-hour class actions and matters involving harassment, discrimination, retaliation and wrongful termination. He began his career in a general litigation firm, representing companies in employment and business cases, before founding his own law firm that focused entirely on employment litigation. Across his career, Strauss has successfully brokered numerous eight-figure settlements, represented parties in hundreds of arbitrations, argued repeatedly in state and federal courts of appeal, and received countless plaintiff and defense verdicts. In 2022, Strauss became a settlement officer with the Los Angeles County Superior Court's Resolve Law Virtual Mandatory Settlement Conference program and now also serves on the court's Mediation Volunteer Panel and the U.S. District Court, Central District of California's Mediation Panel. In 2023, he turned his attention to being a full-time mediator and arbitrator, specializing in employment law matters.
Strauss is a member of the Ventura County Bar Association (VCBA) and served on its board of directors from 2008-2010. He is the long-time chair of the Steering Committee for the VCBA Lawyer Referral and Information Service. He is also a member of the Association of Business Trial Lawyers, the Los Angeles County Bar Association and the Southern California Mediation Association. Strauss received a commendation from the City of Lancaster, Calif., for his achievement in resolving a wage-and-hour class action in 2014. He was named by Southern California Super Lawyers Magazine as a 'Rising Star' from 2011-2019 and as a 'Super Lawyer' from 2020-2021 and 2023-2025. He earned his J.D. from Wake Forest University School of Law (2006) and his B.A. from the University of California, Berkeley (2001). He studied in the Certificate of Dispute Resolution Program at the Straus Institute for Dispute Resolution at the Pepperdine University School of Law from 2022-2023.
About Judicate West
For more than 30 years, Judicate West has been one of California's leading providers of private dispute resolution services with a distinguished roster of proven neutrals, including retired state and federal court judges plus professional attorney mediators and arbitrators from a wide variety of practice areas. Founded in 1993, the firm prides itself on maintaining the utmost integrity in delivering innovative solutions to all types of civil disputes. The firm's successful formula involves top-tier neutrals, a great company culture and an experienced team of ADR professionals dedicated to delivering gold standard service in alternative dispute resolution (ADR).
Contact:
Judicate West
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
$13.16 Bn Human Growth Hormone (HGH) Market Trends and Forecasts, 2020-2024 & 2025-2030: Strategic R&D Initiatives, Regulatory Approvals, and Collaborations Shaping the Landscape
The Human Growth Hormone market offers significant opportunities driven by the rise in growth hormone deficiencies and aging populations seeking HGH therapy. The demand is boosted by potential anti-aging and wellness benefits, with biosimilars presenting a cost-effective alternative. Key challenges include high costs and ethical issues. Human Growth Hormone (HGH) Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Human Growth Hormone (HGH) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Human Growth Hormone (HGH) Market was valued at USD 6.21 Billion in 2024, and is expected to reach USD 13.16 Billion by 2030, rising at a CAGR of 13.29% This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin - a crucial hormone produced by the pituitary gland - to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement Market Drivers Increasing Prevalence of Growth Hormone Deficiency (GHD)The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions Market Challenges High CostCost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH Market Trends BiosimilarsThe growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.21 Billion Forecasted Market Value (USD) by 2030 $13.16 Billion Compound Annual Growth Rate 13.2% Regions Covered Global Report Scope: Key Market Players Novo Nordisk A/S Eli Lilly and Company Pfizer, Inc. Sandoz International GmbH (Novartis AG) Genentech, Inc. (Roche) Merck KGaA Ferring Pharmaceuticals Ipsen Pharma Teva Pharmaceutical Industries, Ltd. Human Growth Hormone (HGH) Market, By Product: Long Acting Others Human Growth Hormone (HGH) Market, By Application: Growth Hormone (GH) Deficiency Turner Syndrome Idiopathic Short Stature Prader-Willi Syndrome Small for Gestational Age Other Human Growth Hormone (HGH) Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy Human Growth Hormone (HGH) Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Growth Hormone (HGH) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
D-BOX Reports Record Full-Year Revenue and Profitability for Fiscal 2025
Royalty-driven Model delivers Strong Margin Expansion and Cash Generation; Leadership Transition positions Company for Next Phase of Growth All dollar amounts are expressed in Canadian currency(1) Please refer to "non-IFRS and other financial performance measures" in this press release Fiscal 2025 Highlights Record total revenues of $42.8 million, up 8% vs. FY 2024 Record royalties of $11 million, up 27% vs. FY 2024 Adjusted EBITDA1 of $7.3 million, or 17% of total revenues, up 9 pts vs. FY 2024 Net profit of $3.9 million, up 254% year-over-year, or fully diluted EPS of $0.02 Cash flow from operating activities of $7.3 million Liquidity of approximately $16 million as of March 31, 2025 Fourth Quarter Highlights Total revenues of $8.6 million, down 15% vs. Q4 2024 Royalties of $2.2 million, up 5% year-over-year Adjusted EBITDA margin1 of 18%, up 12 pts vs. Q4 2024 Net profit of $0.7 million MONTREAL, June 10, 2025 (GLOBE NEWSWIRE) -- D-BOX Technologies Inc. ('D-BOX' or the "Company") (TSX: DBO) today reported financial results for its fourth quarter and full year ended March 31, 2025. 'In Q4 2025, D-BOX delivered robust performance with strong royalty growth, improved profitability, and a resilient core business,' said Brigitte Bourque, Chair of the Board. 'For the full fiscal year 2025, the Company achieved record revenues and net income, driven by the strength of our royalty-focused model and disciplined expense control.' Q4 and Full-Year 2025 Operating Results In Q4 2025, total revenues were $8.6 million, down 15% year-over-year, primarily reflecting the earlier-than-expected fulfillment of Theatrical system sales in Q3, partially offset by growth in Simulation training and Sim racing markets. The $3.4 million decline in Theatrical system sales was partially offset by strong growth in royalties and Sim racing. Royalties increased by 5 percent to $2.2 million, driven by an expanded global footprint reaching 1,012 screens, up 9% from the previous year, as well as successful Hollywood content with blockbusters in the fourth quarter including Captain America: Brave New World, Sonic the Hedgehog 3 and Mufasa: The Lion King. Simulation and training and Sim racing customer groups also grew 47% and 108% year-over-year, respectively, in the fourth quarter. Total revenues also benefited from favourable movements in currency exchange rates. For the full year, D-BOX reported record total revenues of $42.8 million, up 8% compared to fiscal 2024. Excluding the impact of our exit from the direct-to-consumer (DTC) hardware market, FY 2025 revenue would have increased by just over 10% year-over-year. Royalties reached $11 million, accounting for an increased 26% share of the Company's revenue mix. Adjusted EBITDA1 for the year totaled $7.3 million, representing an 18% Adjusted EBITDA margin1, reflecting prudent cost control. Net profit was $3.9 million, with operating cash flow of $7.3 million. Given the inherent variability and seasonality of quarterly sales, we emphasize the importance of assessing the Company's performance on a trailing twelve-month basis. (Amounts are in thousands of Canadian dollars) Q4 2025 Q4 2024 Var.($) Var. (%) FY 2025 FY 2024 Var.($) Var. (%) Revenues from System sales Theatrical 992 4,443 (3,451) (78%) 10,362 11,305 (943) (8%) Simulation and training 2,408 1,635 773 47% 8,606 8,825 (219) (2%) Sim racing 2,682 1,290 1,392 108% 10,020 7,112 2,908 41% Other 286 685 (399) (58%) 2,771 3,656 (885) (24%) Total system sales 6,368 8,053 (1,685) (21%) 31,759 30,898 861 3% Rights for use, rental and maintenance ("royalties") 2,241 2,126 115 5% 11,028 8,699 2,329 27% Total Revenues 8,609 10,179 (1,570) (15%) 42,787 39,597 3,190 8% Leadership Transition As announced on June 4, 2025, the Board appointed Naveen Prasad as Interim CEO, effective June 10, following the departure of Sébastien Mailhot. 'It has been an incredible journey over the past five years,' said Sébastien Mailhot. 'I am very proud of how we have grown revenues and significantly improved profitability while building a team that is now well-positioned for the future. I leave knowing that D-BOX has tremendous opportunities ahead. I wish Naveen and the broader team continued success.' 'We are confident that Naveen will be effective driving the next phase of strategic growth and value creation for all stakeholders,' added Ms. Bourque. Balance Sheet and Liquidity D-BOX closed fiscal 2025 in a position of financial strength, with $7.3 million in operating cash flow, low-cost total debt of $1.2 million, and available liquidity including the undrawn line of credit, of approximately $16 million. SUPPLEMENTAL FINANCIAL DATA - UNAUDITED (Amounts are in thousands of Canadian dollars) Q4 2025 Q4 20242 Var. (%) FY 2025 FY 20242 Var. (%) Total Revenues 8,609 10,179 (15%) 42,787 39,597 8% Gross profit 4,661 4,734 (2%) 22,327 18,660 20% Operating expenses 3,875 4,052 (4%) 17,991 17,005 6% Operating income 786 682 15% 4,336 1,655 162% Adjusted EBITDA1 1,578 620 155% 7,311 3,056 139% Financial expenses 61 97 (37%) 452 590 (23%) Net profit 720 585 23% 3,858 1,058 265% Basic and diluted EPS 0.003 0.003 n.m. 0.017 0.005 260% Gross margin1 54% 47% 7 p.p. 52% 47% 5 p.p. Operating expenses as % of total revenues1 45% 40% 5 p.p. 42% 43% (1 p.p.) Operating margin1 9% 7% 2 p.p. 10% 4% 6 p.p. Adjusted EBITDA margin1 18% 6% 12 p.p. 17% 8% 9 p.p. Cash flows provided by operating activities 7,324 3,125 134% As at (in thousands of Canadian dollars) Mar. 31, 2025 Mar. 31, 2024 Total debt1 1,221 2,468 Cash and cash equivalents 7,812 2,916 Net cash (net debt) 1 6,591 448 Adjusted EBITDA (LTM) 1 7,311 3,056 Total debt to adjusted EBITDA (LTM) 1 0.2x 0.8x 1) Please refer to "non-IFRS and other financial performance measures" in this press release2) Results for the fourth quarter and full year 2024 reflect a $0.5 million one-time gain on the sale of an investment. n.m.= not meaningful This release should be read in conjunction with the Company's audited consolidated financial statements and the Management's Discussion and Analysis dated June 10, 2025. These documents are available at NON-IFRS AND OTHER FINANCIAL PERFORMANCE MEASURES D-BOX uses the following non-IFRS financial performance measures in its MD&A and other communications. The non-IFRS measures do not have any standardized meaning prescribed by IFRS and are unlikely to be comparable to similarly titled measures reported by other companies. Investors are cautioned that the disclosure of these metrics is meant to add to, and not to replace, the discussion of financial results determined in accordance with IFRS. Management uses both IFRS and non-IFRS measures when planning, monitoring and evaluating the Company's performance. The non-IFRS performance measures are described as follows: Adjusted EBITDA EBITDA represents earnings before interest and financing, income taxes and depreciation and amortization. Adjustments to EBITDA are for items that are not necessarily reflective of the Company's underlying operating performance. As there is no generally accepted method of calculating EBITDA, this measure is not necessarily comparable to similarly titled measures reported by other issuers. Adjusted EBITDA provides useful and complementary information, which can be used, in particular, to assess profitability and cash flow from operations. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by total revenues. A reconciliation of net profit to Adjusted EBITDA margin is in the Company's Management's Discussion and Analysis dated June 10, 2025. Total Debt, Net Debt and Total Debt to Adjusted EBITDA Total debt is defined as the total bank indebtedness, long-term debt (including any current portion), and net debt is calculated as total debt net of cash and cash equivalents. The Company considers total debt and net debt to be important indicators for management and investors to assess the financial position and liquidity of the Company and measure its financial leverage. These measures do not have any standardized meanings prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Total debt to Adjusted EBITDA ratio is calculated as total net debt divided by the last four quarters Adjusted EBITDA. We believe that total debt to Adjusted EBITDA is a useful metric to assess the Company's ability to manage debt and liquidity. Supplementary Financial Measures Gross margin is defined as gross profit divided by total revenues. Operating expenses as a percentage of sales are defined as operating expenses divided by total revenues. Operating margin is defined as operating income divided by net sales. ABOUT D-BOX D-BOX creates and redefines realistic, immersive experiences by moving the body and sparking the imagination through effects: motion, vibration and texture. D-BOX has collaborated with some of the best companies in the world to deliver new ways to enhance great stories. Whether it's films, video games, music, relaxation, virtual reality applications, metaverse experience, themed entertainment or professional simulation, D-BOX creates a feeling of presence that makes life resonate like never before. D-BOX Technologies Inc. (TSX: DBO) is headquartered in Montreal with presence in Los Angeles and China. Visit DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS Certain information included in this press release may constitute 'forward-looking information' within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, activities, objectives, operations, strategy, business outlook, and financial performance and condition of the Company, or the assumptions underlying any of the foregoing. In this document, words such as 'may', 'would', 'could', 'will', 'likely', 'believe', 'expect', 'anticipate', 'intend', 'plan', 'estimate' and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information, by its very nature, is subject to numerous risks and uncertainties and is based on several assumptions which give rise to the possibility that actual results could differ materially from the Company's expectations expressed in or implied by such forward-looking information and no assurance can be given that any events anticipated by the forward-looking information will transpire or occur, including but not limited to the future plans, activities, objectives, operations, strategy, business outlook and financial performance and condition of the Company. Forward-looking information is provided in this press release for the purpose of giving information about Management's current expectations and plans and allowing investors and others to get a better understanding of the Company's operating environment. However, readers are cautioned that it may not be appropriate to use such forward-looking information for any other purpose. Forward-looking information provided in this document is based on information available at the date hereof and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The risks, uncertainties and assumptions that could cause actual results to differ materially from the Company's expectations expressed in or implied by the forward-looking information include, but are not limited to, international trade regulations; concentration of clients; dependence on suppliers; performance of content; exchange rate between the Canadian dollar and the U.S. dollar; ability to implement strategy; consumer preferences and trends; political, social and economic conditions; strategic alliances; credit risk; competition; access to content; technology standardization; future funding requirements; distribution network; indebtedness; global health crises; warranty, recalls and claims; dependence on key personnel and labour relations; legal, regulatory and litigation; intellectual property; security and management of information; and reputational risk through social media. These and other risk factors that could cause actual results to differ materially from expectations expressed in or implied by the forward-looking information are outlined under 'Risk Factors' in the Company's management's discussion and analysis for the period ended March 31, 2025, and discussed in greater detail in the most recently filed Annual Information Form dated June 10, 2025, a copy of which is available on SEDAR+ at Except as may be required by Canadian securities laws, the Company does not intend nor does it undertake any obligation to update or revise any forward-looking information contained in this press release to reflect subsequent information, events, circumstances or otherwise. The Company cautions readers that the risks described above are not the only ones that could have an impact on it. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial may also have a material adverse effect on the Company's business, financial condition or results of operations. CONTACT INFORMATION Josh Chandler Chief Financial OfficerD-BOX Technologies Inc.514-928-8043jchandler@
Yahoo
3 hours ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
